Company news
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) news
Reviva Pharmaceuticals Holdings, Inc. news releases on 6ix. Latest, Jun 23, 2026: Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum…
Press releases & updates
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
June 23, 2026
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 12, 2026
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
April 23, 2026
Reviva Announces Letter to Shareholders
April 15, 2026
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
March 29, 2026
Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering
March 22, 2026
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
January 8, 2026
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
December 29, 2025
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
December 23, 2025
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 13, 2025
Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025
November 12, 2025
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
November 10, 2025
Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference
October 29, 2025
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
October 28, 2025
Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners
October 7, 2025
Reviva to Participate in the 4th Annual Roth Healthcare Opportunities Conference
October 2, 2025
Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference
September 23, 2025
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
September 18, 2025
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering
September 17, 2025
Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 14, 2025
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
June 26, 2025
Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
June 5, 2025
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
June 2, 2025
Reviva to Participate in Upcoming Investor Conferences in May 2025
May 20, 2025
Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 15, 2025
Reviva to Participate in the A.G.P. Healthcare Company Showcase
May 13, 2025
Reviva to Participate in the Citizens Life Sciences Conference
April 29, 2025
Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting
April 24, 2025
Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights
March 31, 2025
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
March 30, 2025
Reviva Announces Proposed Public Offering
December 15, 2024
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants
December 15, 2024
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
December 15, 2024
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 13, 2024
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
November 11, 2024
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024
November 5, 2024
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
September 8, 2024
Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules
August 20, 2024
Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024
Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis
August 5, 2024
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
July 8, 2024
Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 27, 2024
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 13, 2024
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
April 14, 2024
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
February 19, 2024
Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones
January 3, 2024
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 15, 2023
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 13, 2023
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
October 29, 2023
Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia
September 24, 2023